Department of Oncology, Oncology Centre, Addenbrooke's Hospital, Cambridge, UK.
Expert Rev Anticancer Ther. 2009 Nov;9(11):1583-98. doi: 10.1586/era.09.135.
Metastatic melanoma (MM) carries a dismal prognosis, as it is largely resistant to conventional cytotoxic chemotherapy, biochemotherapy and immunotherapy. There is, therefore, a pressing need to identify new, effective treatments to improve outcomes from MM. Innovative approaches in oncology drug development include anti-angiogenic strategies, in the form of monoclonal antibodies and small-molecule kinase inhibitors. In this review we aim to present current concepts and controversies surrounding the role of angiogenesis and anti-angiogenic therapies in MM, alluding to other tumor types in which increasing knowledge may supply avenues for future directions in melanoma research and management. An overview of angiogenesis and its importance in melanoma progression is presented, highlighting the key molecules that represent potential therapeutic targets. The results of using anti-angiogenic strategies in preclinical and clinical trials are discussed and future perspectives for anti-angiogenic therapies in MM are considered.
转移性黑色素瘤（MM）预后较差，因为它对常规细胞毒性化疗、生物化疗和免疫疗法有很大的抵抗力。因此，迫切需要确定新的、有效的治疗方法来改善 MM 的治疗效果。肿瘤药物开发的创新方法包括抗血管生成策略，如单克隆抗体和小分子激酶抑制剂。在这篇综述中，我们旨在介绍围绕血管生成和抗血管生成治疗在 MM 中的作用的当前概念和争议，并暗示在其他肿瘤类型中，不断增加的知识可能为黑色素瘤研究和管理的未来方向提供途径。概述了血管生成及其在黑色素瘤进展中的重要性，强调了代表潜在治疗靶点的关键分子。讨论了在临床前和临床试验中使用抗血管生成策略的结果，并考虑了 MM 中抗血管生成治疗的未来前景。
